amylin glp-1 dual agonist Identification and utility exploration of a highly potent and long-acting bullfrog analogue in GLP-1 and combination therapy Amylin Receptor Agonist - an

Then researchers had an idea: what if you could amplify this natural signal

This twice daily injectable established the entire drug class

are not legally sold for human use in the U.S

Lilly 2026 How Retatrutide Compares to Tirzepatide and Semaglutide Head-to-head network meta-analysis data shows retatrutide produces greater absolute and percentage weight loss than tirzepatide: a mean difference of 16.34 kg absolute weight reduction and 23.77% percentage weight loss versus tirzepatide's 16.79%

The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse

Currently available treatment with proven outcomes Semaglutide FDA-approved for diabetes (Ozempic), obesity (Wegovy), and CV risk reduction with 7+ years of clinical and post-marketing data Cardiovascular risk reduction Semaglutide SELECT trial demonstrated 20% MACE reduction in 17,604 patients -- the first anti-obesity drug with proven cardiovascular benefit Maximum weight loss potential Retatrutide Phase 2 data showed 24.2% weight loss at 48 weeks with weight curves still declining, though Phase 3 confirmation is required Metabolic liver disease (MASLD/MASH) Retatrutide Glucagon receptor agonism directly promotes hepatic fat oxidation, a mechanistic advantage for liver-specific outcomes Oral administration preference Semaglutide Only incretin-class drug available as an oral tablet (Rybelsus), with higher-dose oral formulations under development Type 2 diabetes with established treatment guidelines Semaglutide Integrated into clinical guidelines with multiple approved doses and formulations, extensive comparative data, and guideline positioning Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly